References
- Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72
- Lewington S, Clarke R, Qizilbash N, et al. Agespecific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13
- Rupp H, Jäger B. The renninangiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J Clin Basic Cardiol 2001;4:47–51
- Givertz MM. Manipulation of the renin–angiotensin system. Circulation 2001;104:E14–18
- Peach MJ. Renin–angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;57:313–70
- Schmidt B, Drexler H, Schieffer B. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. Am J Cardiovasc Drugs 2004;4: 361–8
- Verma S, Strauss M. Angiotensin receptor blocker and myocardial infarction. BMJ 2004;329:1248–9
- Ram CVS. Angiotensin blockage with eprosartan: vascular and functional implications. Curr Med Res Opin 2007;23\(Suppl. 5):S5–S11
- Robins GW, Scott LJ. Eprosartan: a review of its use in the management of hypertension. Drugs 2005;65:2355–77
- Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
- Bohm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Saf 2002;25:599–611
- Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218–26
- Rupp H. Risk reduction by preventing stroke: need for lockage of angiotensin II and catecholamines? Curr Med Res Opin 2007;23\(Suppl. 5):S25–S29
- Balt JC, Mathy MJ, Pfaffendorf M, et al. Inhibition of facilitation of sympathetic neurotransmission and angiotensin IIinduced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001;19:2241–50
- Guimaraes S, Carneiro C, Brandao F, et al. A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta. Naunyn Schmiedebergs Arch Pharmacol 2004;370:262–9
- Ohlstein EH, Brooks DP, Feuerstein GZ, et al. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244–51
- Arosio E, De MS, Prior M, et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 2005;23: 1923–7
- Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartantreated chronic renal failure. J Am Soc Nephrol 2004;15:2902–7
- Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6month data from >10,000 patients and review of literature. Curr Med Res Opin 2007;23\(Suppl. 5): S13–S18
- De Backer G. The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. Curr Med Res Opin 2007;23 (Suppl. 5):S19–S24